Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia

Authors

Amber Afzal, Washington University School of Medicine in St. Louis
Mark A Fiala, Washington University School of Medicine in St. Louis
Meagan A Jacoby, Washington University School of Medicine in St. Louis
Matthew J Walter, Washington University School of Medicine in St. Louis

Journal

Blood Advances

Publication Date

8-8-2023

Volume

7

Issue

15

First Page

3838

Last Page

3841

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023009818

Rights and Permissions

Afzal A, Fiala MA, Jacoby MA, Walter MJ. Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia. Blood Adv. 2023 Aug 8;7(15):3838-3841. doi: 10.1182/bloodadvances.2023009818. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Afzal, Amber; Fiala, Mark A; Jacoby, Meagan A; and Walter, Matthew J, "Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia." Blood Advances. 7, 15. 3838 - 3841. (2023).
https://digitalcommons.wustl.edu/oa_4/2339

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.